(Q27004711)

A. Smyth

series ordinal

2

1 reference

language of work or name

1 reference

December 2012

1 reference

Therapeutic advances in respiratory disease

published in

1 reference

volume

6

1 reference

issue

6

1 reference

page(s)

363-73

1 reference

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Inhaled antibiotics for long-term therapy in cystic fibrosis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France

21 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

21 March 2017

https://api.crossref.org/works/10.1177%2F1753465812459899

A critical review of the fluoroquinolones: focus on respiratory infections

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis.

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Ciprofloxacin safety in paediatrics: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Antimicrobials: Modes of Action and Mechanisms of Resistance

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Mechanism of action of and resistance to quinolones

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Defining a pulmonary exacerbation in cystic fibrosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Use of ciprofloxacin in cystic fibrosis patients

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3509170

Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.

31 May 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Oral fluoroquinolones and the risk of retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Fluoroquinolone-induced suicidal ideation and suicidality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753465812459899

Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis

21 January 2018

1 reference

12 December 2020

Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis

1 reference

12 December 2020

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

12 December 2020

Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study

1 reference

12 December 2020

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa

1 reference

12 December 2020

Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin

1 reference

12 December 2020

Identifiers

DOI

10.1177/1753465812459899

1 reference

1 reference

PubMed publication ID

22968160

1 reference